JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16

Phase 1

Completed

Conditions: Healthy Volunteers and Asthma

Interventions: Drug: Placebo (asthmatic patients)
Drug: CNTO 3157 (healthy participants)
Drug: Placebo (healthy participants)
Drug: CNTO 3157 (asthmatic patients)
Other: HRV-16

First Posted Date: 2012-10-11

Last Posted Date: 2014-12-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 76

Registration Number: NCT01704040

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Tumor or Lymphoma

First Posted Date: 2012-10-10

Last Posted Date: 2019-05-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 188

Registration Number: NCT01703481

A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

Phase 3

Completed

Conditions: Prostate Neoplasms

Interventions: Drug: Placebo
Drug: Abiraterone acetate
Drug: Prednisone

First Posted Date: 2012-09-27

Last Posted Date: 2019-07-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 214

Registration Number: NCT01695135

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TMC435
Drug: Atorvastatin
Drug: Simvastatin

First Posted Date: 2012-09-21

Last Posted Date: 2013-03-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 36

Registration Number: NCT01689623

Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-38518168 10 mg
Drug: JNJ-38518168 3 mg
Drug: JNJ-38518168 30 mg
Drug: Ketoconazole 200 mg

First Posted Date: 2012-09-21

Last Posted Date: 2013-07-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 33

Registration Number: NCT01690286

A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: Topiramate

First Posted Date: 2012-09-21

Last Posted Date: 2024-11-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 139

Registration Number: NCT01689649

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisolone

First Posted Date: 2012-09-17

Last Posted Date: 2019-03-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 82

Registration Number: NCT01685983

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: JNJ-38518168 (3 mg)
Drug: JNJ-38518168 (10 mg)
Drug: JNJ-38518168 (30 mg)
Drug: Methotrexate

First Posted Date: 2012-09-06

Last Posted Date: 2019-03-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 272

Registration Number: NCT01679951

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2012-09-05

Last Posted Date: 2013-09-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 15

Registration Number: NCT01678573

A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: No intervention

First Posted Date: 2012-09-03

Last Posted Date: 2024-10-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 169

Registration Number: NCT01677598

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy